Regulatory FDA approves AstraZeneca’s Imfinzi-BCG combination for NMIBC therapy Pharmaceutical TechnologyAstraZeneca has secured FDA approval for Imfinzi in combination with BCG induction and maintenance therapy for adults with BCG-nave, high-risk NMIBC.OncologyRead full story pharminent June 1, 2026 (Last updated: June 1, 2026) Pharmaceutical Technology AstraZeneca has secured FDA approval for Imfinzi in combination with BCG induction and maintenance therapy for adults with BCG-nave, high-risk NMIBC. Oncology Read full story Post navigation Previous: Previous PostNext: Lilly and Hanmi sign $1.26bn licensing deal for sonefpeglutide Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
